BioSpace News Archive

Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 38,000 shares of its common stock to one employee outside Fusion’s 2020 Stock Option and Incentive Plan.

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A. Liu and Meenu Chhabra Karson to its Board of Directors, effective January 3, 2023.

ImmunoGen, Inc. announced that on December 29, 2022, and in connection with the previously announced appointment of Michael J. Vasconcelles, MD as ImmunoGen’s Executive Vice President, Research, Development, and Medical Affairs, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase 960,000 shares of its common stock under the ImmunoGen, Inc.

MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that the company will participate in the 41st Annual J.P. Morgan Healthcare Conference.

Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation for IBI351 for the treatment of advanced non-small cell lung cancer patients with KRASG12C mutation that have received at least one prior line of systemic therapy.

Duality Biologics announced a license agreement with Adcendo ApS, a biotech company focused on the development of breakthrough ADCs for the treatment of underserved cancers.

Ascentage Pharma announced that its Chairman and CEO, Dr. Dajun Yang, has accepted an invitation to speak at the 41st Annual J.P. Morgan Healthcare Conference, at 08:30 AM, January 11, 2023, Pacific Time, to provide an update on Ascentage Pharma’s progress with its proprietary innovation and global R&D.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2, randomized, placebo-controlled trial to evaluate its development-stage medicine daxdilimab.

RayzeBio to Present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023.

bioAffinity Technologies, Inc . (NASDAQ: BIAF; BIAFW) announced today that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent application titled “ Porphyrin Compounds and Compositions Useful for Treating Cancer ” for the targeted delivery of novel cancer treatments.